<DOC>
	<DOCNO>NCT00947115</DOCNO>
	<brief_summary>Infection human papillomavirus ( HPV ) clearly establish necessary cause cervical cancer . This study design evaluate long-term immunogenicity safety GSK Biologicals ' 580299 HPV vaccine 10 year administration first dose HPV vaccine ( Month 0 ) primary study NCT 00196937 . This protocol post deal objective &amp; outcome measure extension phase Year 5 Year 10 . The objective &amp; outcome measure primary phase extension phase year 4 present separate protocol posting ( NCT 00196937 ) .</brief_summary>
	<brief_title>Evaluation Long-term Immunogenicity Safety Human Papillomavirus ( HPV ) Vaccine Healthy Female Subjects</brief_title>
	<detailed_description>Subjects age 15-55 year time entry primary study ( NCT00196937 ) . No vaccine administer extension study . Results outcome measure describe analysis study report record . Please refer record mention respective outcome measure title .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol . A female enrol NCT00332475 receive three dos GSK 580299 vaccine . Written inform consent obtain subject . Use investigational nonregistered product ( drug vaccine ) plan use study period . Chronic administration ( define 14 consecutive day ) immunosuppressant immunemodifying drug occur less three month prior blood sampling . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Administration immunoglobulins and/or blood product within three month precede blood sampling . Administration plan administration HPV vaccine , three dos HPV16/18 vaccine administer NCT00332475 study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Cervical cancer</keyword>
	<keyword>HPV vaccine</keyword>
</DOC>